NRIX250117C2500
- 20.30
- 0.000.00%
Nurix Therapeutics Newsroom
Express News | Nurix Therapeutics : Anticipate Sharing Additional Clinical Data About Ongoing Phase 1B Expansion Cohort in 2025
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia
Express News | Nurix Therapeutics Receives U.S. FDA Fast Track Designation for Nx-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?
A Quick Look at Today's Ratings for Nurix Therapeutics(NRIX.US), With a Forecast Between $29 to $35
Nurix Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Nurix Therapeutics Inc : H.c. Wainwright Raises Target Price to $35 From $30
Nurix Therapeutics (NRIX) Receives a Buy From Barclays
BTIG Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
Oppenheimer Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Nurix Therapeutics (NRIX) Receives a Buy From Stifel Nicolaus
Nurix Therapeutics Reports Promising Trial Results for NX-5948
Optimistic Buy Rating for Nurix Therapeutics' NX-5948 Driven by Strong Efficacy in CLL and Strategic Expansion Plans
Express News | Nurix Therapeutics Inc - Favorable Safety Profile Across All Doses Tested
Nurix Therapeutics Initiated at Outperform by BMO Capital
BMO Capital Initiates Nurix Therapeutics(NRIX.US) With Buy Rating, Announces Target Price $35
Piper Sandler Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $35
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Nurix Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1 Clinical Trial Cancer Data for BTK Degrader NX-5948.
Nurix Therapeutics Announces Webcast To Review New Data From Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting